Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06929806 · ClinicalTrials.gov registry record · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
A Phase 3 study of Chronic Heart Failure and Iron Deficiencies, sponsored by Pharmacosmos A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,900
- Enrollment target
- 1
- Study location
NCT06929806: Recruiting Phase 3 study of Chronic Heart Failure and Iron Deficiencies, sponsored by Pharmacosmos A/S.
NCT06929806 is a Phase 3 study of Chronic Heart Failure and Iron Deficiencies that is actively recruiting participants, run by Pharmacosmos A/S. The registered enrollment target is 1,900 participants, above the 264-participant average among 12 other Chronic Heart Failure trials with a reported enrollment target (620% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06929806, a Phase 3 study of Chronic Heart Failure and Iron Deficiencies, is actively recruiting participants, sponsored by Pharmacosmos A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,900 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if the IV Iron treatment ferric derisomaltose helps in the treatment of chronic heart failure in people with iron deficiency. The main question it aims to answer is: • How many participants are admitted to the hospital or die from a disease in the heart or blood vessels Researchers will compare treatment with ferric derisomaltose to no treatment with ferric derisomaltose. This will be done to see how well ferric derisomaltose works. Participants will: * Be randomized 50/50 to either treatment with Ferric derisomaltose or to no treatment with ferric derisomaltose * All participants receives standard of care * Visit site 4-5 times and have 7 video/phone-calls
Conditions Studied
Interventions
- DRUG Ferric Derisomaltose
Study Locations (1)
California
- Private clinic - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,900 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 3 |
What NCT06929806 shows while recruiting
NCT06929806 is an interventional study that assigns participants to a tested intervention. Its 1,900 participants enrollment target places it among the larger protocols in the corpus, above the 264-participant average among 12 other Chronic Heart Failure trials with a reported enrollment target (620% higher).
The record links to 2 conditions, with Chronic Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Ferric Derisomaltose is the first listed.
NCT06929806 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06929806 about?
NCT06929806 is a clinical study titled "Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure". The goal of this clinical trial is to learn if the IV Iron treatment ferric derisomaltose helps in the treatment of chronic heart failure in people with iron deficiency. The main question it aims to answer is: • How many participants are admitted to the hospital or die from a disease in the heart o...
What is the current status of trial NCT06929806?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,900 participants. The study started on 2025-05-01. Estimated completion is 2027-12-01.
What conditions does trial NCT06929806 study?
This clinical trial studies the following conditions: Chronic Heart Failure, Iron Deficiencies.
What interventions are being tested in trial NCT06929806?
The interventions under investigation include: Ferric Derisomaltose (DRUG).
Who is sponsoring clinical trial NCT06929806?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06929806 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06929806's enrollment target sits among peer trials
1,900 1st of 12 higher than 12 of 12 other Chronic Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
RECRUITING · NA
-
Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment
RECRUITING · NA
-
The HEARTFELT Study
RECRUITING · NA
-
R&D Study to Evaluate Cordio's Usability and to Collect Patient Speech Utterances
ACTIVE NOT RECRUITING
-
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
- NCT07280065 · 1,900 participants · Phase 3
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI